000			01641nam a2200277 4500
003			PC7366
005			20220226062802.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92238 _aAzcárate, Isabel G. _eInstituto de Investigación imas12
100			_91902 _aBautista, José M. _eInstituto de Investigación i+12
100			_aDíez, Amalia _91901 _eInstituto de Investigación i+12
100			_aMarín García, Patricia _92240 _eInstituto de Investigación i+12
100			_aPuyet, Antonio _91900 _eInstituto de Investigación i+12
245	0	0	_aInsights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin. _h[artículo]
260			_bBritish journal of pharmacology, _c2013
300			_a169(3):645-58.
500			_aFormato Vancouver: Azcárate IG, Marín-García P, Camacho N, Pérez-Benavente S, Puyet A, Diez A et al. Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin. Br J Pharmacol. 2013 Jun;169(3):645-58.
501			_aPMID: 23488671
504			_aContiene 69 referencias
520			_aBACKGROUND AND PURPOSE: Blood-stage Plasmodium parasites cause morbidity and mortality from malaria. Parasite resistance to drugs makes development of new chemotherapies an urgency. Aminoacyl-tRNA synthetases have been validated as antimalarial drug targets. We explored long-term effects of borrelidin and mupirocin in lethal P. yoelii murine malaria.
710			_9625 _aInstituto de Investigación imas12
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682711/ _yAcceso libre
942			_n0 _2ddc _cART
999			_c7366 _d7366